Product details Net content: 10 mg per vial Format: Lyophilized material Container: 3 mL glass vial Lot/batch: Recorded on every vial label Intended use Non-clinical laboratory research Analytical reference and assay development Use only in accordance with institutional SOPs and applicable regulatory requirements Not for human or animal consumption Not for clinical, therapeutic, or diagnostic use Certificate of Analysis (COA) For complete quality information, refer to the second and third product images showing the current Certificate of Analysis for Retatrutide Canada 10mg
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (surpass-3): A randomised, open-label, parallel-group, phase 3 trial
Experts have verified through peer-reviewed studies that GLP-1 therapy improves heart health, lowers blood pressure, and cuts down risks tied to type 2 diabetes
Liraglutide normalized the content of malondialdehyde, nitric oxide, IL-6, and matrix metalloproteinases-2 and 9 while increasing superoxide dismutase and IL-10 in the sciatic nerve
